Analyst Ratings For AzurRx BioPharma Inc (NASDAQ:AZRX)
Today, CIBC initiated coverage on AzurRx BioPharma Inc (NASDAQ:AZRX) with a Outperform with a price target of $6.00.
There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on AzurRx BioPharma Inc (NASDAQ:AZRX) is Buy with a consensus target price of $6.6667 per share, a potential 145.10% upside.
Some recent analyst ratings include
- 10/17/2018-AzurRx BioPharma Inc (NASDAQ:AZRX) has coverage initiated with a Outperform ➝ Outperform rating and $6.00 price target
- 10/17/2018-AzurRx BioPharma Inc (NASDAQ:AZRX) has coverage initiated with a Outperform rating and $6.00 price target
- 12/6/2016-AzurRx BioPharma Inc (NASDAQ:AZRX) has coverage initiated with a Buy rating and $7.00 price target
Recent Insider Trading Activity For AzurRx BioPharma Inc (NASDAQ:AZRX)
AzurRx BioPharma Inc (NASDAQ:AZRX) has insider ownership of 7.20% and institutional ownership of 18.61%.
- On 6/30/2017 Pelican Partners Llc, Major Shareholder, sold 160,000 with an average share price of $3.19 per share and the total transaction amounting to $510,400.00.
Recent Trading Activity for AzurRx BioPharma Inc (NASDAQ:AZRX)
Shares of AzurRx BioPharma Inc closed the previous trading session at 2.75 up +0.25 10.00% with 2.6 shares trading hands.